[Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.]
The oral calcimimetics, cinacalcet, is reported to be effective on secondary hyperparathyroidism resistant to classical treatment like phosphate binders or vitamin D receptor activator. The problem that gastrointestinal adverse events cause poor adherence, drug discontinuation, and insufficient dose escalation remains unsolved. The novel injectable calcimimetic, etelcalcetide, is recently developed and is expected to reduce such adverse events and improve the therapeutic effects on moderate to severe secondary hyperparathyroidism. Further studies are needed to demonstrate the potential benefits of etelcalcetide compared to cinacalcet.
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan.
Naoto
N
Hamano
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Japan.
Masafumi
M
Fukagawa
D057966:Calcimimetic Agents / Q000627:therapeutic use*; D000069449:Cinacalcet / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications
D057966:Calcimimetic Agents; D000069449:Cinacalcet